RhumbLine Advisers’s aTyr Pharma ATYR Stock Holding History

RhumbLine Advisers’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.2K	Sell	30,412 -72,734	-71%	-$47.5K	﹤0.01%	3828
2026 Q1	$80.4K	Buy	103,146 +3,384	+3%	+$2.86K	﹤0.01%	3491
2025 Q4	$78.1K	Sell	99,762 -22,645	-18%	-$18.6K	﹤0.01%	3548
2025 Q3	$88.2K	Sell	122,407 -1,751	-1%	-$7.93K	﹤0.01%	3555
2025 Q2	$629K	Buy	+124,158	New	+$488K	﹤0.01%	2533

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RhumbLine Advisers's ATYR Position: Q2 2026 in Review

RhumbLine Advisers reduced its aTyr Pharma (ATYR) stake by 71% in Q2 2026, selling an estimated $47.5K and leaving 30,412 shares worth $18.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3828.

RhumbLine Advisers first reported a position in ATYR in Q2 2025 and has held it in 5 quarters since. The position peaked at $629K in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

RhumbLine Advisers held 30,412 shares of aTyr Pharma worth $18.2K as of Q2 2026.
RhumbLine Advisers sold 72,734 aTyr Pharma shares in Q2 2026, an estimated $47.5K.
aTyr Pharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3828 holding.
RhumbLine Advisers first reported a position in aTyr Pharma in Q2 2025 and has held it in 5 quarters since.
RhumbLine Advisers's aTyr Pharma position peaked at $629K in Q2 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.